Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study (Q38437507)
Jump to navigation
Jump to search
scientific article published on 20 January 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study |
scientific article published on 20 January 2014 |
Statements
1 reference
Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study (English)
1 reference
Kazuomi Kario
1 reference
Ningling Sun
1 reference
Ouppatham Supasyndh
1 reference
Sang Hong Baek
1 reference
Akiko Inubushi-Molessa
1 reference
Ying Zhang
1 reference
Hiromi Gotou
1 reference
Martin Lefkowitz
1 reference
Jack Zhang
1 reference
20 January 2014
1 reference
1 reference
63
1 reference
4
1 reference
698-705
1 reference
Identifiers
1 reference
1 reference